Meeting
2018 ASCO Annual Meeting
Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.
Authors
Yoon-Koo Kang
Department of Oncology, Asan Medical Center, Seoul, Korea, Republic of (South)
Yoon-Koo Kang , Jae-Joon Kim , Changhoon Yoo , Mo Youl Beck , Jungeun Ma , Min-Hee Ryu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT02889328
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11537)
DOI
10.1200/JCO.2018.36.15_suppl.11537
Abstract #
11537
Poster Bd #
282
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
First Author: Hyung-Don Kim
Poster
2020 ASCO Virtual Scientific Program
LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.
First Author: Axel Le Cesne
Poster
2019 Gastrointestinal Cancers Symposium
Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial.
First Author: Jian Li
Poster
2015 Gastrointestinal Cancers Symposium
Efficacy and safety of regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: A multicenter study based on the management access program.
First Author: Myoung Kyun Son